Q-omics provides the consensus-scored ZFP91P1 profile across patient tissues and cancer cell-line models. ZFP91P1 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, ZFP91P1 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, ZFP91P1 RNA expression shows 9,624 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight LUAD, COAD, and THYM as cancer lineages where ZFP91P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZFP91P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZFP91P1 survival associations across molecular data types. ZFP91P1 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZFP91P1 RNA expression–survival associations across cancer types. High ZFP91P1 expression shows unfavorable associations in MESO, but favorable associations in LUAD, HNSC, KIRP, LUSC and READ. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for ZFP91P1 RNA expression.
This table summarizes ZFP91P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for ZFP91P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZFP91P1 shows lower tumor expression in LUAD and higher tumor expression in COAD, KIRC, UCEC, LIHC and PRAD. The COAD box plot shows higher ZFP91P1 RNA expression in tumor versus normal tissue (log2 FC = +0.150, t-test p < 0.001).
This table shows molecular features associated with ZFP91P1 in patient tissues and cancer cell lines. In patient samples, ZFP91P1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
